NDA 018553 · Ani Pharms
Inderal La
Propranolol Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Nov 7, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1983
Apr 19, 1983
Approved uses
4
Original approval plus efficacy supplements
Registered trials
392
63 Phase 3, 46 recruiting
FAERS reports
20,561
14,089 serious, 2,107 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 27, 2026.
INDICATIONS AND USAGE Hypertension Propranolol hydrochloride extended-release capsules USP are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules USP are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules USP are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Migraine Propranolol hydrochloride extended-release capsules USP are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Hypertrophic Subaortic Stenosis Propranolol hydrochloride extended-release capsules USP improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.
Mechanism: Mechanism of Action The mechanism of the antihypertensive effect of propranolol has not been established. Among the factors that may be involved in contributing to the antihypertensive action include: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use of propranolol. Effects of propranolol on plasma volume appear to be minor and somewhat variable. In...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 18, 1987 Supplement 13 · Efficacy Review
- Aug 20, 1985 Supplement 8 · Efficacy
- Jan 9, 1984 Supplement 1 · Efficacy
- Apr 19, 1983 Original approval · Type 3 - New Dosage Form
4 products under this application
- INDERAL LA · PROPRANOLOL HYDROCHLORIDE 60MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- INDERAL LA · PROPRANOLOL HYDROCHLORIDE 80MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- INDERAL LA · PROPRANOLOL HYDROCHLORIDE 120MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- INDERAL LA · PROPRANOLOL HYDROCHLORIDE 160MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Propranolol" as an intervention, any sponsor and status, largest first.
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation TrialPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00911508 · 2,204 participants · Start Nov 13, 2009 · Primary completion Dec 31, 2017
Drug: Rate or Rhythm Control Therapy · For: Atrial Fibrillation; Arrhythmia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 118 sites in all
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyPivotal-lookingRecruiting
Mayo ClinicAcademic, hospital or other
NCT06972056 · 1,335 participants (planned) · Start Jul 9, 2025 · Primary completion Mar 1, 2029
Drug: Atogepant 60 mg; Propranolol 160 mg and 1 more · For: Migraine
Sites: Hazel Green, Alabama; Flagstaff, Arizona; Phoenix, Arizona · 39 sites in all
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
Center for Vascular Pathology, MoscowAcademic, hospital or other
NCT05106179 · 1,000 participants (planned) · Start Dec 2021 · Primary completion Dec 2022
Drug: Atenolol Pill; Propranolol Pill · For: Spinal Tumor; Spinal Hemangioma; Beta Blocker Toxicity
Sites: Moscow, Russia
- A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of MigrainePivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00236561 · 786 participants · Start Apr 2001
Drug: topiramate, propranolol · For: Migraine; Common Migraine; Classic Migraine and 1 more
- Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T StatusPivotal-lookingStatus unknown
Hamad Medical CorporationIndustry
NCT04508244 · 771 participants (planned) · Start Dec 29, 2020 · Primary completion Dec 31, 2024
Drug: Placebo; Propranolol · For: Trauma; Brain Injuries; Stress Reaction and 2 more
Sites: Doha, Qatar
- Assessment of Mechanisms of Improved Wound HealingPivotal-lookingCompleted
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00673309 · 644 participants · Start Jul 2000 · Primary completion Apr 2011
Drug: Insulin High Dose; oxandrolone and 8 more · For: Burns
Sites: Galveston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,090
- drug ineffective1,819
- nausea1,590
- fatigue1,370
- headache1,334
- diarrhoea1,061
- dyspnoea1,018
- dizziness1,016
- product use in unapproved indication956
- product use issue922
- pain870
- vomiting856
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 466 |
| 2005 | 575 |
| 2006 | 536 |
| 2007 | 447 |
| 2008 | 381 |
| 2009 | 530 |
| 2010 | 642 |
| 2011 | 623 |
| 2012 | 730 |
| 2013 | 577 |
| 2014 | 601 |
| 2015 | 833 |
| 2016 | 886 |
| 2017 | 741 |
| 2018 | 865 |
| 2019 | 936 |
| 2020 | 917 |
| 2021 | 1,165 |
| 2022 | 1,575 |
| 2023 | 1,731 |
| 2024 | 2,098 |
| 2025 | 1,483 |
| 2026 | 1,222 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Inderal La (Propranolol HCl)
2024 spending
$7.2M
Beneficiaries
261
1,324 claims
Per beneficiary
$27,694
$71.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,790,625 |
| 2021 | $11,435,127 |
| 2022 | $9,453,606 |
| 2023 | $8,234,374 |
| 2024 | $7,228,104 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis.
Steenen SA, van Wijk AJ, van der Heijden GJ, et al. · J Psychopharmacol 2016 · Comparative Study, Meta-Analysis
- A randomized, controlled trial of oral propranolol in infantile hemangioma.
Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. · N Engl J Med 2015 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis.
Stritzke A, Kabra N, Kaur S, et al. · J Perinatol 2019 · Meta-Analysis, Systematic Review
- Randomized controlled trial of propranolol on social communication and anxiety in children and young adults with autism spectrum disorder.
Beversdorf DQ, Ferguson B, Hunter S, et al. · Psychopharmacology (Berl) 2024 · Randomized Controlled Trial, Multicenter Study
- Propranolol Normalizes Metabolomic Signatures Thereby Improving Outcomes After Burn.
Rehou S, de Brito Monteiro L, Auger C, et al. · Ann Surg 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.
· JAMA 1982 · Clinical Trial, Randomized Controlled Trial
Sponsor: Ani Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.